Tests amivantamab with chemotherapy against cetuximab for left-sided colorectal cancer
Tests amivantamab and chemotherapy against cetuximab in adults with left-sided colorectal cancer.
Key facts
- Who runs it
- Janssen Research & Development, LLC
- Where
- Birmingham, Cambridge, Edinburgh, Hull, Leeds, London, Northwood, and Sutton, United KingdomSee the 9 sitesAlso in 21 other countries, 231 sites
- Trial code
- Registry title
- A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 1,000 people, planned
- Started
- 18 Oct 2024
- Expected to end
- 20 Jan 2032
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Amivantamab
- Cetuximab
- 5-fluorouracil
- Leucovorin calcium/Levoleucovorin
- Oxaliplatin
- Irinotecan Hydrochloride
- Record updated
- 3 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with left-sided colorectal cancer that cannot be removed by surgery or has spread, and who have not had treatment for this stage. The tumor must be KRAS, NRAS and BRAF wild-type.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Adenocarcinoma of left-sided colorectal cancer that cannot be removed by surgery or is metastatic, with measurable disease (RECIST v1.1)
- Earlier treatment
- No earlier systemic therapy for unresectable or metastatic colorectal cancer. Earlier adjuvant or neoadjuvant treatment is allowed if its last course ended more than 12 months before the cancer came back or spread.
- Biomarker or test result
- Tumor must be KRAS, NRAS and BRAF wild-type (WT) by local and/or central testing. Participants must agree to give fresh tumor tissue.
Main reasons for not taking part
- Interstitial lung disease, pneumonitis or pulmonary fibrosis, now or in the past
- Known allergy or intolerance to amivantamab, cetuximab, mFOLFOX6 or FOLFIRI components
- Another cancer that could affect the safety or results of the trial
- Known dMMR/MSI-H status together with a HER2-positive/amplified tumor
- Earlier treatment with drugs targeting EGFR, MET or VEGF
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Have histologically or cytologically confirmed adenocarcinoma of the left-sided colorectal cancer. Participants must have unresectable or metastatic disease
- Determined to have Kirsten rat sarcoma viral oncogene (KRAS), neuroblastoma RAS viral oncogene homolog (NRAS), and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type (WT) tumor by local and/or central testing (if available)
- Must agree to the submission of fresh tumor tissue
- Have measurable disease according to RECIST v1.1
- Has not received any prior systemic therapy for unresectable or metastatic colorectal cancer (CRC). Prior adjuvant/neoadjuvant therapy in the non-metastatic disease is permitted. However, the last course of adjuvant or neoadjuvant chemotherapy must have concluded greater than (>) 12 months prior to CRC recurrence/metastases
- Have an eastern cooperative oncology group (ECOG) performance status (PS) of 0 or 1
Who cannot take part
- Has a prior or concurrent second malignancy other than the disease under study or one whose natural history or treatment is likely to interfere with any study endpoints of safety or the efficacy of the study treatment(s)
- Has medical history of (noninfectious) interstitial lung disease (ILD) /pneumonitis/pulmonary fibrosis or has current ILD/pneumonitis/pulmonary fibrosis, or where suspected ILD/pneumonitis/pulmonary fibrosis cannot be ruled out by imaging at screening
- Has known allergies, hypersensitivity, or intolerance to excipients of any of the following: (a) amivantamab or cetuximab, (b) any component of mFOLFOX6 and, (c) any component of FOLFIRI
- Has prior exposure to any agents that target epidermal growth factor receptor (EGFR), mesenchymal epithelial transition (MET) or vascular endothelial growth factor (VEGF)
- Participant with known mismatch repair deficiency (dMMR)/ high microsatellite instability (MSI-H) status and human epidermal growth factor receptor 2 (HER2)-positive/amplified tumor
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- How many different drug treatment plans (such as chemotherapy) have you had for cancer that has spread?
- Has a test of your tumour shown a change (mutation) in the KRAS, NRAS or BRAF genes?
- Do you have now, or have you ever had, a lung disease with scarring or swelling of the lungs, such as pulmonary fibrosis (scarring of the lungs) or pneumonitis?
Where in United Kingdom
Also in 21 other countries, 231 sites
- Birmingham Heartlands HospitalBirmingham, United KingdomTaking people
- Addenbrooke's HospitalCambridge, United KingdomTaking people
- Western General HospitalEdinburgh, United KingdomTaking people
- Castle Hill HospitalHull, United KingdomTaking people
- St James University HospitalLeeds, United KingdomTaking people
- St. Bartholomew's HospitalLondon, United KingdomTaking people
- University College HospitalLondon, United KingdomTaking people
- Mount Vernon Cancer CentreNorthwood, United KingdomTaking people
- Royal Marsden Hospital (Sutton)Sutton, United KingdomTaking people
About the trial
What the trial wants to find out
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus cetuximab and mFOLFOX6 or FOLFIRI in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS)/ Neuroblastoma RAS viral oncogene homolog (NRAS) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) wild type (WT) unresectable or metastatic left-sided colorectal cancer.
The 2 groups in the trial
- Arm A: Amivantamab in Combination With ChemotherapyTreatment being tested
Participants will receive amivantamab in combination with chemotherapy (mFOLFOX6 \[chemotherapy consisting of 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and oxaliplatin\] or FOLFIRI \[chemotherapy consisting of 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride\]) for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met.
Treatment: Amivantamab, 5-fluorouracil, Leucovorin calcium/Levoleucovorin, Oxaliplatin, and Irinotecan Hydrochloride
- Arm B: Cetuximab in Combination With ChemotherapyExisting treatment, for comparison
Participants will receive cetuximab in combination with chemotherapy (mFOLFOX6 or FOLFIRI) for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met.
Treatment: Cetuximab, 5-fluorouracil, Leucovorin calcium/Levoleucovorin, Oxaliplatin, and Irinotecan Hydrochloride
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- Plain-language title
- Tests amivantamab with chemotherapy against cetuximab for left-sided colorectal cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06662786, who can take part
- Record updated
- 3 November 2026